Ikarian Capital’s TG Therapeutics TGTX Stock Holding History

Ikarian Capital’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-117,903	Closed	-$3.51M	–	209
2025 Q4	$3.51M	Sell	117,903 -57,056	-33%	-$1.86M	0.27%	75
2025 Q3	$6.32M	Sell	174,959 -34,979	-17%	-$1.15M	0.64%	36
2025 Q2	$7.56M	Sell	209,938 -127	-0.1%	-$4.73K	1.45%	25
2025 Q1	$8.28M	Sell	210,065 -81,175	-28%	-$2.73M	1.02%	16
2024 Q4	$8.77M	Buy	+291,240	New	+$8.36M	1.19%	18
2023 Q4	–	Sell	-32,547	Closed	-$272K	–	181
2023 Q3	$272K	Buy	+32,547	New	+$454K	0.03%	118
2022 Q2	–	Sell	-2,292	Closed	-$21K	–	200
2022 Q1	$21K	Sell	2,292 -98,447	-98%	-$1.14M	﹤0.01%	192
2021 Q4	$1.91M	Buy	+100,739	New	+$2.62M	0.29%	64
2020 Q1	–	Sell	-316,200	Closed	-$3.51M	–	172
2019 Q4	$3.51M	Buy	+316,200	New	+$2.4M	0.57%	47

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ikarian Capital's TGTX Position: Q1 2026 in Review

Ikarian Capital sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 117,903 shares — an estimated $3.51M sold.

Ikarian Capital first reported a position in TGTX in Q4 2019 and held it in 9 quarters. The position peaked at $8.77M in Q4 2024. 364 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Ikarian Capital reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
Ikarian Capital sold 117,903 TG Therapeutics shares in Q1 2026, an estimated $3.51M.
Ikarian Capital first reported a position in TG Therapeutics in Q4 2019 and held it in 9 quarters.
Ikarian Capital's TG Therapeutics position peaked at $8.77M in Q4 2024.
364 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.